Ophthotech Corp (OPHT) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Ophthotech Corp (OPHT) Reports Acquisition of Inception 4 Inc. to Expand Innovative Retinal Disease Pipeline
October 31, 2018 6:46 AM EDTOphthotech Corporation (NASDAQ: OPHT) announced today that it has acquired Inception 4, Inc., a privately held company backed by Versant Ventures, expanding Ophthotechs therapeutic pipeline in age-related retinal indications. Through this acquisition, Ophthotech gains worldwide development and commercialization rights to Inception 4s small molecule inhibitors of HtrA1 (high temperature requirement A serine peptidase 1 protein). HtrA1 is... More
